Quantitative analysis of aggregation-solubility relationship by in-silico solubility prediction
Tadaaki Mashimo1,2, Yoshifumi Fukunishi3, Masaya Orita2,4, Naoko Katayama2,4, Shigeo Fujita2,5, Haruki Nakamura3,6
1Information and Mathematical Science Laboratory Inc., Tokyo, Japan; 2Japan Biological Informatics Consortium (JBIC), Tokyo, Japan; 3Biomedicinal Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan; 4Chemistry Research Labs, Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan; 5Astellas Research Technology Inc., Ibaraki, Japan; 6Institute for Protein Research, Osaka University, Osaka, Japan
Abstract: Aggregator (frequent hitter) compounds show non-selective binding activity against any target protein and must be removed from the compound library to reduce false positives in drug screening. A previous study suggested that aggregators show high hydrophobicity. The LogS values of aggregators and non-aggregators were estimated by the artificial neural network (ANN) model, the multi-linear regression (MLR) model, and the partial least squares regression (PLS) models, with the weighted learning (WL) method, and the results showed the same trend. The WL method is weighted on the data of the learning set molecules that are similar to the test molecule and improves the prediction accuracy. Bayesian analysis was applied, revealing a simple relationship between aggregation and solubility. Namely, the molecules with LogS > −5 were non-aggregators. In contrast, most of the molecules with LogS < −5 were aggregators. We also made a simple look-up table of probability of aggregation depending on the molecular weight and the number of hetero-atoms.
Keywords: aggregator, frequent hitter, compound library, solubility prediction, generalized-Born accessible-surface area, GBSA
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.